The phospholipase A 2 (PLA 2 ) family of proteins includes lipolytic enzymes that liberate the sn-2 fatty acyl chains from phospholipids to yield nonesterified fatty acids and lysophospholipids. The purpose of this review is to discuss recent findings showing distinct roles of several of these PLA 2 enzymes in inflammatory metabolic diseases such as diabetes and atherosclerosis.
INTRODUCTION
The phospholipase A 2 (PLA 2 ) family of proteins includes lipolytic enzymes that catalyze the hydrolysis of the ester bond at the sn-2 position of phospholipids to yield free fatty acids and lysophospholipids. Currently, these enzymes are classified into five major groups with many subgroups depending on their functions and cellular locations. The secreted PLA 2 (sPLA 2 ) enzymes are smallsecreted proteins of 14-18 kDa. The lipoproteinassociated PLA 2 is also a secreted enzyme but it has platelet-activating factor acetylhydrolase activity and is associated with plasma lipoproteins. The other three groups of PLA 2 enzymes are located intracellularly: the cytosolic PLA 2 s (molecular sizes of 61-114 kDa) that are calcium-dependent, the calcium-independent PLA 2 s (85-88 kDa) that are also present in the cytosol, and the lysosomal PLA 2 that functions exclusively in the lysosomes with optimal activity at lower pH. Research over the past decade using genetically modified mouse models and association studies in humans have indicated distinct roles of each PLA 2 in biological processes such as digestion, tissue injury/repair, host defense, inflammation, atherosclerosis, and obesity/ diabetes. This review will focus primarily on the recently discovered role of the group 1B phospholipase A 2 (PLA2G1B) in obesity/diabetes, hyperlipidemia, and atherosclerosis. The influence of other PLA 2 s in these metabolic disorders will be discussed briefly for comparison. Readers interested in these PLA 2 enzymes are referred to several excellent recent review articles for more details [1 && ,2-4].
GROUP 1B PHOSPHOLIPASE A 2
The PLA2G1B is a secreted phospholipase expressed primarily in the acinar cells of the pancreas and to a lesser extent also in the lung and islet b-cells.
In pancreatic acinar cells, PLA2G1B is found within zymogen granules along with other digestive enzymes. Upon meal feeding, contents within the zymogen granules are released into pancreatic juice and transported to the intestinal lumen wherein the enzymes can mediate nutrient digestion and absorption. On the basis of its enzymatic activity in hydrolyzing phospholipids, the role of PLA2G1B in the digestive tract was presumed to be the hydrolysis of phospholipids, thereby contributing to the necessary remodeling of lipid particles in the intestinal lumen prior to lipid nutrient absorption. However, knockout mouse studies revealed that PLA2G1B is not the only phospholipid hydrolytic enzyme in the digestive tract, and other phospholipases in the intestine can compensate for the lack of this enzyme in catalyzing phospholipid digestion and intestinal lipid absorption in PLA2G1B-null mice. Genome-wide association studies have identified polymorphisms in the PLA2G1B gene as a determinant of central obesity in humans [5] . The association between PLA2G1B gene polymorphism and obesity in humans can be recapitulated in genetically modified mouse models, with Pla2g1bnull mice displaying resistance to diet-induced obesity, hyperglycemia, and hyperinsulinemia, whereas transgenic overexpression of the Pla2g1b gene in pancreas accentuates these metabolic diseases [6,7 & ]. The differences in sensitivity to dietinduced metabolic diseases between wild type Pla2g1b þ/þ mice with Pla2g1b -/and Pla2g1b-transgenic mice are not due to differences in food intake. Although the most straightforward explanation for their metabolic differences is that PLA2G1B may be required for complete phospholipid hydrolysis when lipid input into the intestinal lumen exceeds the capacity of the compensatory mechanism, a similar amount of fat was found to be absorbed between these animals when they were fed the high fat diet. Additionally, the fat-fed Pla2g1b -/mice absorbed more fat than chow-fed Pla2g1b þ/þ mice yet their body weight gains were similar [6]. The Pla2g1b þ/þ and Pla2g1b -/mice also displayed similar fat absorption efficiency when maintained on a low-fat chow diet, yet the Pla2g1b -/mice displayed increased glucose tolerance and insulin sensitivity compared with their wild-type counterparts under these conditions [6] . These results indicated that PLA2G1B has a direct role in regulating adiposity, glucose metabolism, and insulin sensitivity, and this unique property of PLA2G1B is not shared by other phospholipases in the intestinal tract.
One difference in intestinal phospholipid digestion between Pla2g1b þ/þ and Pla2g1b -/mice is the lipolytic products formed and absorbed after meal consumption. The Pla2g1b þ/þ mice absorbed significantly more lysophospholipids into the liver and circulation compared with Pla2g1b -/mice, but the absorption of phospholipid-derived fatty acids and phosphatidylcholine-associated choline was found to be similar between Pla2g1b þ/þ and Pla2g1b -/mice [8]. These results suggested that the compensatory enzyme for phospholipid digestion in the intestinal lumen in the absence of PLA2G1B is not specific for the ester bond at the sn-2 position of phospholipids, but can release both sn-1 and sn-2 fatty acyl chains from phospholipids to yield two nonesterified fatty acids and glycerophosphocholine for absorption by enterocytes. In contrast, luminal digestion of diet-derived and/or biliary-derived phospholipids by PLA2G1B yields nonesterified fatty acids and lysophospholipids that can be rapidly absorbed by intestinal cells.
Differences in lysophospholipid absorption accounted for the differences between Pla2g1b þ/þ , Pla2g1b -/-, and Pla2g1b-transgenic mice in their sensitivity to diet-induced metabolic diseases. Postprandial lysophospholipid levels were significantly lower in Pla2g1b -/mice and higher in Pla2g1b-transgenic mice compared with those observed in wildtype Pla2g1b þ/þ mice. The infusion of lysophospholipids into Pla2g1b À/À mice, to levels similar to the levels observed during the postprandial state of Pla2g1b þ/þ mice, abolished the protective effects of Pla2g1b gene deletion against exaggerated postprandial insulin resistance and hyperglycemia [8] . Lysophospholipids promote postprandial hyperglycemia by reducing glucose uptake by the liver, heart, and muscle tissues, as well as suppressing insulinstimulated glycogen synthesis in the liver [8] .
KEY POINTS
The PLA2G1B promotes lysophospholipid absorption, which suppresses hepatic fatty acid oxidation leading to promotion of obesity, diabetes, and hyperlipidemia.
Unique role of each PLA 2 in generating bioactive lipid metabolites that promote inflammation and inflammatory metabolic diseases.
Pharmacological inhibitions of PLA 2 enzyme activities are effective strategies to reduce diet-induced obesity, diabetes, hyperlipidemia, and atherosclerosis.
Lysophospholipids administration also ameliorated the enhanced hepatic fatty acid oxidation observed in Pla2g1b -/mice, thereby increasing substrate availability for deposition into adipose tissues to promote obesity [9 & ]. Lysophospholipids reduce fatty acid oxidation by inhibiting the expression of peroxisome proliferator-activated receptor (PPAR)-a, PPAR-d, and PPAR-g genes, as well as genes for proteins responsible for fatty acid transport and utilization such as CD36 and uncoupling protein-
The reduced hepatic fatty acid oxidation due to PLA2G1B-mediated lysophospholipid absorption also increases fatty acid substrates available for triglyceride biosynthesis [10 & ]. Additionally, lysophospholipids are also efficiently reacylated to phospholipids, as well as promote triglyceride synthesis [11] . Lysophospholipids also prevent premature intracellular degradation of apolipoprotein B in the liver [12] . Therefore, PLA2G1B-mediated lysophospholipid absorption promotes hyperlipidemia by accentuating hepatic VLDL synthesis and secretion after fat feeding [10 & ]. Moreover, PLA2G1B gene inactivation has also been reported to improve plasma clearance of triglyceride-rich lipoproteins in high fat-fed mice [10 & ], suggesting that lysophospholipids derived from PLA2G1B-mediated phospholipid hydrolysis in the digestive tract may also suppress the expression of LDL receptor and/or LDL receptor-related proteins in the liver. Taken together, these results indicate that the underlying mechanism by which PLA2G1B gene inactivation protects against diet-induced hyperlipidemia is also mediated via reducing lysophospholipid absorption after fat feeding, thereby ameliorating diet-induced postprandial VLDL synthesis and increasing plasma clearance of triglyceride-rich lipoproteins. The lower plasma lipid levels in Pla2g1b -/mice are likely to reduce lipid deposition to adipose tissues, skeletal muscle, and the vessel wall, thereby may also indirectly suppress diet-induced obesity, insulin resistance, and atherosclerosis through this mechanism. A schematic diagram depicting the model of how PLA2G1B influences lipid metabolism and related metabolic diseases is shown in Figure 1 .
The resistance of Pla2g1b gene inactivated mice to diet-induced obesity, diabetes, and hyperlipidemia suggests that the PLA2G1B protein may be a novel therapeutic target for treatment of these metabolic disorders. This possibility has been explored in a preclinical model testing the efficacy of the PLA2G1B inhibitor methyl indoxam to suppress body weight gain and hyperglycemia in response to a high fat/high carbohydrate diet in mice. When mixed with food and administered orally, methyl indoxam did not alter food intake or lipid nutrient Fatty acids generated directly from lipase-catalyzed hydrolysis of chylomicron-TG, as well as from VLDL hydrolysis are deposited in adipose tissues to promote adiposity as well as transported to skeletal muscle to promote insulin resistance (I.R.). The LDL generated from increased lipoprotein secretion can also accumulate in the vessel wall to promote atherosclerosis. Figure (b) shows pathway in Pla2g1b -/mice, wherein reduced LysoPL absorption due to Pla2g1b inactivation results in increased hepatic fatty acid oxidation (bold arrow) and reduced TG synthesis and VLDL secretion, ultimately leading to reduced fatty acid deposition in adipose tissue and skeletal muscle and decreased LDL accumulation in the vessel wall. absorption but significantly reduced postprandial lysophospholipid levels in a concentration-dependent manner, indicating the suppression of PLA2G1B activity in vivo [13] . Importantly, oral methyl indoxam administration reduced high fat/high carbohydrate diet-induced body weight gain in a dose-dependent manner [13] . Fasting blood glucose levels and glucose tolerance in high fat/high carbohydrate-fed mice were also dramatically improved with methyl indoxam treatment, to levels similar to those observed in mice fed a low-fat control diet [13] . Oral methyl indoxam administration had no effect on body weight and blood glucose levels in chow-fed animals, thus indicating that the reduced body weight gain and improved glucose tolerance with methyl indoxam treatment were not due to adverse effects but a direct consequence of suppressing PLA2G1B activity in vivo. Finally, whereas 10 weeks of feeding the high fat/high carbohydrate diet increased fasting plasma cholesterol levels in wild-type C57BL/6 mice, the inclusion of methyl indoxam in the high fat/high carbohydrate meal suppressed diet-induced hypercholesterolemia, reducing plasma cholesterol levels to levels observed in chow-fed wild-type mice or in Pla2g1b -/mice fed either chow or high fat/high carbohydrate diet (Fig. 2) . The effectiveness of oral methyl indoxam administration to reduce diet-induced obesity, hyperglycemia, and hypercholesterolemia in mice is consistent with the possibility that PLA2G1B inhibition may be a potentially effective oral therapeutic option for treatment of metabolic diseases. However, it is important to note that in-vitro experiments have documented that methyl indoxam is a general inhibitor capable of inhibiting the activities of other secretory PLA 2 enzymes in addition to PLA2G1B [14] . Although cell culture studies failed to detect methyl indoxam transport from the apical to the basolateral side of intestinal cells [13, 15] , thus suggesting that methyl indoxam protection against diet-induced metabolic diseases through direct inhibition of PLA2G1B in the intestinal lumen, in-vivo measurements revealed limited but significant bioavailability of orally fed methyl indoxam [13] . Whether a nonabsorbable PLA2G1B inhibitor, which presumably would be more advantageous with potentially less systemic side-effects, can be an effective option, or if inhibition of other PLA 2 enzymes in addition to PLA2G1B inhibition is necessary to reduce diet-induced obesity, diabetes, and hypercholesterolemia remains to be determined.
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2
The lipoprotein-associated PLA 2 (Lp-PLA 2 ) is also a secreted protein and is made by lymphocytes, macrophages, and mast cells. In addition to the hydrolysis of phospholipids, Lp-PLA 2 is also capable of degrading biologically active oxidized phospholipids (oxPLs) and platelet activating factor. Studies exploring the role of Lp-PLA 2 in metabolic diseases have focused primarily on atherosclerosis. Nevertheless, the role of Lp-PLA 2 in atherosclerosis has not been resolved completely. The hydrolysis of oxPLs by Lp-PLA 2 generates lysophospholipids and oxidized fatty acids, which are proinflammatory and promote atherosclerosis. The oxPLs have also been reported to have antiinflammatory properties and function in a negative feedback manner to blunt macrophage inflammatory response [16] . These observations suggest that Lp-PLA 2 is proatherogenic by increasing inflammatory response, as well as reducing the ability to tempered inflammation in response to vascular insults. Surprisingly, adenovirus-mediated transfer of the Lp-PLA 2 gene suppressed injury-induced neointimal hyperplasia and reduced spontaneous atherosclerosis in apoE -/mice [17] , suggesting that Lp-PLA 2 is atheroprotective in mice. However, a recent study reported that pharmacological inhibition of Lp-PLA 2 activity also ameliorated inflammation and atherosclerotic plaque formation in apoE -/mice [18 && ]. The differences between these two studies have not been resolved. Week 0
Week 10 FIGURE 2. PLA2G1B inactivation protects against dietinduced hypercholesterolemia. Fasting plasma cholesterol levels were measured from wild-type (WT) Pla2g1b þ/þ mice and Pla2g1b -/-(PLA2G1B KO) mice before (solid bars) and 10 weeks after feeding a high fat/high carbohydrate diet (open bars). Results showed elevation of plasma cholesterol levels in WT mice after high fat/high carbohydrate feeding, and the diet-induced hypercholesterolemia was not observed in WT mice when PLA2G1B activity was inhibited with oral methyl indoxam administration or in mice with Pla2g1b gene inactivation.
Thus, the role of Lp-PLA 2 in atherosclerosis development in mice remains unclear.
Mallat et al.
[1 && ] suggested that the role of Lp-PLA 2 in atherosclerosis might be different between humans and mice because the enzyme is associated with HDL in mice and with LDL in humans. In humans, high Lp-PLA 2 levels and activities are associated with coronary heart disease and inflammation [19] . Reducing circulating Lp-PLA 2 levels in patients with acute coronary syndrome was associated with plaque regression [20 && ]. Plasma Lp-PLA 2 levels are also associated with high waisthip ratio, plasma triglyceride cholesterol and LDLcholesterol levels, and Lp-PLA 2 levels are higher in patients with metabolic syndrome than in normal patients [21] . Taken together, these results indicate that Lp-PLA 2 promotes metabolic diseases in humans, suggesting that Lp-PLA 2 may also be a target for intervention. Preclinical and clinical testing of efficacy of the Lp-PLA 2 -specific inhibitor darapladib in reducing cardiovascular and metabolic diseases is currently underway [22] [23] 24 & ].
OTHER SECRETED PHOSPHOLIPASE A 2 ENZYMES
Other secreted PLA 2 s are similar to PLA2G1B and Lp-PLA 2 in the production of proinflammatory mediators such as nonesterified fatty acids and lysophospholipids. The group IIa PLA 2 PLA2G2A is the most abundant PLA 2 enzyme in human serum. Unfortunately, the most commonly used mouse strain for studying cardiovascular and metabolic diseases, C57BL/6 mouse is a natural mutant of PLA2G2A. Nevertheless, overexpression of the human PLA2G2A gene increases atherosclerosis in wild type and LDL receptor-deficient C57BL/6 mice [25, 26] , indicating that PLA2G2A is proatherogenic. This enzyme accelerates atherosclerosis through multiple mechanisms including: the hydrolysis of LDL-associated phospholipids to promote remodeling of LDL to smaller and denser LDL particles with increased retention to matrix proteoglycans at the vessel wall [27] , induction of LDL oxidation and cellular oxidative stress [28] , and direct binding to sPLA 2 receptors on cell surfaces to promote inflammatory cytokine secretion [29] . In the vessel wall, PLA2G2A can be localized to atherosclerotic lesion areas but the enzyme is not present in normal arteries [30] . The expression of PLA2G2A by vascular smooth muscle cells is induced during inflammation [31, 32] . Tissue inflammation also elevates PLA2G2A expression in adipose tissues [32] , suggesting that PLA2G2A not only contributes to atherosclerosis but may also be a contributing factor in other inflammatory metabolic diseases such as diabetes. The potential of sPLA 2 inhibitors for treatment of both of these metabolic disorders has been suggested in a recent review article [23] .
INTRACELLULAR PHOSPHOLIPASE A 2 ENZYMES
The two most prominent intracellular PLA 2 enzymes are the calcium-dependent cPLA 2 a (PLA2G4A) and the calcium-independent iPLA 2 (PLA2G6). Both enzymes are important inflammatory mediators, responding to extracellular signaling to provide distinct lipid mediators at different intracellular sites that are required for leukocyte chemotaxis [4] . The cPLA 2 a enzyme is selective for liberating sn-2 arachidonic acids from phospholipids, thereby is essential for signal-activated generation of arachidonic acid-derived lipid metabolites during cell activation. In contrast, iPLA 2 lacks acyl chain specificity but prefers phosphatidic acid instead of phospholipid substrates. Both cPLA 2 agenerated arachidonic acid and iPLA 2 -mediated lysophosphatic acid production are required for monocyte chemotaxis to monocyte chemoattractant protein-1. Thus, activation of these intracellular PLA 2 s by extracellular stimulation is also proinflammatory, and potentially contributory to both atherosclerosis and diabetes. Although these results suggest intracellular PLA 2 inhibition may be another approach for treatment of these inflammatory metabolic diseases, a recent report showing cPLA 2 inhibition increases CD36 expression and foam cell formation in a macrophage cell line raising caution to this strategy [33 && ].
CONCLUSION
Depending on the anatomic site of expression, each member of the PLA 2 family of enzymes serves a distinct role in normal physiology in response to meal consumption and infection, but also generates active lipid metabolites that promote inflammatory metabolic diseases including atherosclerosis, hyperlipidemia, obesity, and diabetes. The PLA2G1B is expressed primarily in the pancreatic acinar cells and participates in remodeling of dietary lipids in the intestinal lumen prior to lipid nutrient absorption. However, PLA2G1B elevates lysopholipid levels postprandially leading to an increase in susceptibility of obesity, diabetes, and hyperlipidemia. The other secretory PLA 2 s generates active lipid metabolites that promote oxidative stress and inflammatory cytokine production, whereas the major intracellular PLA 2 enzymes, cPLA 2 a, and iPLA 2 are activated in response to extracellular stimuli to relay signals for leukocyte chemotactic responses in accentuating inflammatory metabolic diseases. The development of specific drugs that target one or more of these PLA 2 enzymes should be considered as novel strategies to treat chronic inflammatory metabolic diseases such as diabetes and atherosclerosis.
